Halozyme to Present at Upcoming Investor Conferences PR Newswire SAN DIEGO, Nov. 27, 2024 SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today...
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions PR Newswire SAN DIEGO, Nov. 22, 2024 SAN DIEGO, Nov. 22, 2024 /PRNewswire/ -- Halozyme...
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction PR Newswire SAN DIEGO, Nov. 14, 2024 Combination Would Create a Global Innovative Services...
HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS PR Newswire SAN DIEGO, Oct. 31, 2024 Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to...
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE PR Newswire SAN DIEGO, Oct. 24, 2024 Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX...
Halozyme to Report Third Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO, Oct. 23, 2024 SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | -6.98 | -99.7142857143 | 7 | 9.2 | 0.015 | 1227889 | 0.49635887 | CS |
260 | -0.405 | -95.2941176471 | 0.425 | 35 | 0.015 | 2666733 | 0.36991871 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約